ENBREL

Main information

  • Trade name:
  • ENBREL 1 INJ
  • Dosage:
  • 50MG/ML
  • Pharmaceutical form:
  • INJ
  • Composition:
  • 1
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • ENBREL 1 INJ
    India
  • Language:
  • English

Other information

Status

  • Source:
  • Central Drugs Standard Control Organization
  • Last update:
  • 09-08-2016

20-12-2017

Enbrel (Pfizer Limited)

Enbrel (Pfizer Limited)

Enbrel (Active substance: Etanercept) - Centralised - Yearly update - Commission Decision (2017)8994 of Wed, 20 Dec 2017

Europe -DG Health and Food Safety

16-11-2017

ENBREL (Etanercept) Solution ENBREL (Etanercept) Kit [Immunex Corporation]

ENBREL (Etanercept) Solution ENBREL (Etanercept) Kit [Immunex Corporation]

Updated Date: Nov 16, 2017 EST

US - DailyMed

27-6-2017

Erelzi (Sandoz GmbH)

Erelzi (Sandoz GmbH)

Erelzi (Active substance: etanercept) - Centralised - Authorisation - Commission Decision (2017)4482 of Tue, 27 Jun 2017 European Medicines Agency (EMA) procedure number: EMEA/H/C/004192/0000

Europe -DG Health and Food Safety

30-5-2017

Triple Therapy More Cost-Effective Than MTX + Biologic in RA

Triple Therapy More Cost-Effective Than MTX + Biologic in RA

Patients with active rheumatoid arthritis (RA) did as well when switched from methotrexate (MTX) monotherapy to triple-drug therapy (MTX, sulfasalazine, and hydroxychloroquine) as when the biologic drug etanercept was added to ongoing MTX. Triple therapy saved more than $500,000 per patient for each year of good-quality life gained, the researchers found.

US - RxList